ACADIA Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ACAD ACADIA Pharmaceuticals Inc
JLS Nuveen Mortgage and Income Fund
JNJ Johnson & Johnson
QIAN Qiansui International Group Co Ltd
BV Brightview Holdings Inc
PFE Pfizer Inc
MP Mp Materials Corp
WFG West Fraser Timber Co Ltd
MDT Medtronic PLC
ATMR^ Altimar Acquisition Corp II
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program.

Closing Price
$27.42
Day's Change
0.12 (0.44%)
Bid
--
Ask
--
B/A Size
--
Day's High
27.60
Day's Low
26.91
Volume
(Light)
Volume:
1,201,621

10-day average volume:
1,649,987
1,201,621

Upcoming Events

ACAD's fiscal year ends in December
There are no upcoming events for ACAD

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
May 5, 2021Q1 2021 Earnings Release-$0.42-$0.65 to -$0.33-$0.57
February 24, 2021Q4 2020 Earnings Release-$0.42-$0.56 to -$0.35-$0.34
November 4, 2020Q3 2020 Earnings Release-$0.54-$0.704 to -$0.29-$0.29
August 5, 2020Q2 2020 Earnings Release-$0.27-$0.55 to -$0.37-$0.38

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.